Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.55 |
| ▸ | LDHA | P00338 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | SLC28A3 | Q9HAS3 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.36 |
| ▸ | PYGB | P11216 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22047950 | 1.00 | CDK1 (0.55) | CDK1CCNB1LDHAEPHX2MEN1 | |
| Ammonia Solution, Strong SCHEMBL190255 | 0.99 | CDK1 (0.54) | CDK1CCNB1LDHAEPHX2MEN1 | |
| Lindane SCHEMBL8049713 | 0.95 | CDK1 (0.51) | CDK1CCNB1LDHAEPHX2MEN1 | |
| SCHEMBL9619715 | 0.89 | CDK1 (0.56) | CDK1CCNB1LDHAEPHX2MEN1 | |
| SCHEMBL3191785 | 0.88 | CDK1 (0.51) | CDK1CCNB1LDHAEPHX2MEN1 | |
| SCHEMBL3655532 | 0.88 | CDK1 (0.51) | CDK1CCNB1LDHAEPHX2MEN1 | |
| SCHEMBL9241365 | 0.88 | CDK1 (0.53) | CDK1CCNB1LDHAEPHX2MEN1 | |
| SCHEMBL1614945 | 0.88 | LDHA (0.44) | CDK1CCNB1LDHAEPHX2MEN1 | |
| SCHEMBL18167468 | 0.88 | CDK1 (0.55) | CDK1CCNB1LDHAEPHX2MEN1 | |
| SCHEMBL10390144 | 0.88 | CDK1 (0.55) | CDK1CCNB1LDHAEPHX2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 938 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4413074-A1 | ARTICLES CONTAINING MELT PROCESSABLE CELLULOSE ESTER COMPOSITIONS COMPRISING AMORPHOUS BIOFILLER | Eastman Chemical Company (US) | 2024-08-14 | — | — | EP | claimed |
| EP-3394197-B1 | METHOD FOR PRODUCING COLORLESS AND AGING-RESISTANT, POLYACRYLATE-BASED PRESSURE-SENSITIVE ADHESIVE COMPOUNDS | TESA SE (DE) | 2024-06-12 | — | — | EP | claimed |
| CN-114437146-B | Production process of sucralose-6-acetate | 福州大学 | 2023-12-08 | — | — | CN | claimed |
| WO-2023059853-A1 | ARTICLES CONTAINING MELT PROCESSABLE CELLULOSE ESTER COMPOSITIONS COMPRISING AMORPHOUS BIOFILLER | EASTMAN CHEMICAL COMPANY (US) | 2023-04-13 | — | — | WO | claimed |
| CN-115590135-A | Essence, application thereof and carbonated beverage containing essence | 恒枫食品科技有限公司(CN) | 2023-01-13 | — | — | CN | claimed |
| CN-115463069-A | Multi-effect toothpaste for repairing stomatitis and preparation method thereof | 斯钦 | 2022-12-13 | — | — | CN | claimed |
| CN-111281817-B | Preparation method of water-containing bioactive glass toothpaste | 云南白药集团健康产品有限公司 | 2022-08-30 | — | — | CN | claimed |
| US-20220265830-A1 | LONG-ACTING FORMULATIONS AND VEHICLES | DURECT CORPORATION (US) | 2022-08-25 | — | — | US | claimed |
| US-20220257619-A1 | LONG-ACTING FORMULATIONS OF TENOFOVIR ALAFENAMIDE | DURECT CORPORATION | 2022-08-18 | — | — | US | claimed |
| CN-111135104-B | Preparation method of toothpaste capable of repairing enamel | 云南白药集团健康产品有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-1335126-A | Medical solid self-emulsifying composition for ensuring biological active combined material continuous transfer and its producing process | ALFARIX INC (CA) | 2002-02-13 | — | — | CN | claimed |
| EP-1173148-A1 | METHOD OF IMPROVING THE AESTHETIC APPEARANCE OF EPITHELIA | AVON PRODUCTS, INC. (US) | 2002-01-23 | — | — | EP | claimed |
| WO-2000066077-A1 | METHOD OF IMPROVING THE AESTHETIC APPEARANCE OF EPITHELIA | AVON PRODUCTS, INC. (US) | 2000-11-09 | — | — | WO | claimed |
| EP-0610063-B1 | Regioselective enzymatic deacylation of sucrose esters in anhydrous organic media | MCNEIL PPC INC (US) | 2000-05-03 | — | — | EP | claimed |
| US-5897876-A | A WATER-IN-OIL EMULSION COMPRISING A CONTINUOUS HYDROPHOBIC PHASE AND A DISCONTINUOUS AQUEOUS HYDROPHILIC PHASE, SURFACTANT DISPERSANTS AND ACTIVE DRUG FOR ORAL DELIVERY | SHIRE LABORATORIES INC. (US) | 1999-04-27 | — | — | US | claimed |
| CN-1147044-A | Method for manufacturing mica sheet transfer paper | HANTUO COMMODITY ADVERTISEMENT (CN) | 1997-04-09 | — | — | CN | claimed |
| US-5445951-A | Regioselective enzymatic deacylation of sucrose esters in anhydrous organic media | MCNEIL-PPC, INC. (US) | 1995-08-29 | — | — | US | claimed |
| EP-0610063-A2 | Regioselective enzymatic deacylation of sucrose esters in anhydrous organic media | McNEIL-PPC, INC. (US) | 1994-08-10 | — | — | EP | claimed |
| WO-1993010187-A1 | AGRICULTURAL BIODEGRADABLE PLASTICS | INTERNATIONAL OPTICAL TELECOMMUNICATIONS, INC. (US) | 1993-05-27 | — | — | WO | claimed |
| US-5205863-A | Agricultural biodegradable plastics | INTERNATIONAL COMMUNICATIONS & ENERGY (US) | 1993-04-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265830-A1 | LONG-ACTING FORMULATIONS AND VEHICLES | NPY5R, GNRHR, VEGFA | CDK1 4700/4885CCNB1 4384/4885LDHA 3669/4885 |
| US-20220257619-A1 | LONG-ACTING FORMULATIONS OF TENOFOVIR ALAFENAMIDE | ADA, ADAR, TYMP | CDK1 3590/4885CCNB1 4422/4885LDHA 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.